128 related articles for article (PubMed ID: 2186854)
21. What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients.
Coyle C; Short D; Jackson L; Sebire NJ; Kaur B; Harvey R; Savage PM; Seckl MJ
Gynecol Oncol; 2018 Feb; 148(2):254-257. PubMed ID: 29229282
[TBL] [Abstract][Full Text] [Related]
22. [Use of sulprostone in the evacuation of molar pregnancies].
Pinet C; Colau JC
Rev Fr Gynecol Obstet; 1991 Jan; 86(1):53-5. PubMed ID: 2068488
[TBL] [Abstract][Full Text] [Related]
23. Criteria for initiating chemotherapy in patients after evacuation of hydatidiform mole.
Matsui H; Iitsuka Y; Yamazawa K; Tanaka N; Mitsuhashi A; Seki K; Sekiya S
Tumour Biol; 2003; 24(3):140-6. PubMed ID: 14610317
[TBL] [Abstract][Full Text] [Related]
24. Telomerase activity in complete hydatidiform mole.
Bae SN; Kim SJ
Am J Obstet Gynecol; 1999 Feb; 180(2 Pt 1):328-33. PubMed ID: 9988795
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of prophylactic chemotherapy outcome and clinical characteristics in patients of high-risk hydatidiform mole].
Geng S; Feng FZ; Xiang Y; Wan XR; Zhou Y
Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):24-7. PubMed ID: 21429430
[TBL] [Abstract][Full Text] [Related]
26. Identification of patients with persistent trophoblastic disease after complete hydatidiform mole by using a normal 24-hour urine hCG regression curve.
van Cromvoirt SM; Thomas CM; Quinn MA; McNally OM; Bekkers RL
Gynecol Oncol; 2014 Jun; 133(3):542-5. PubMed ID: 24631700
[TBL] [Abstract][Full Text] [Related]
27. Persistent trophoblast disease following partial molar pregnancy.
Wielsma S; Kerkmeijer L; Bekkers R; Pyman J; Tan J; Quinn M
Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):119-23. PubMed ID: 16638033
[TBL] [Abstract][Full Text] [Related]
28. Earlier diagnosis and serum human chorionic gonadotropin regression in complete hydatidiform moles.
Kerkmeijer LG; Massuger LF; Ten Kate-Booij MJ; Sweep FC; Thomas CM
Obstet Gynecol; 2009 Feb; 113(2 Pt 1):326-31. PubMed ID: 19155902
[TBL] [Abstract][Full Text] [Related]
29. Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease?
Earp KE; Hancock BW; Short D; Harvey RA; Fisher RA; Drew D; Sarwar N; Tidy JA; Winter MC; Chien P; Seckl MJ
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():117-119. PubMed ID: 30684876
[TBL] [Abstract][Full Text] [Related]
30. Comparison of human chorionic gonadotropin +beta and invasive trophoblast antigen disappearance rates in serum after evacuation of molar pregnancy.
Van Trommel NE; Sweep FC; Ross HA; Massuger LF; Thomas CM
Int J Mol Med; 2006 Oct; 18(4):705-11. PubMed ID: 16964426
[TBL] [Abstract][Full Text] [Related]
31. Subsequent pregnancy outcome in patients with spontaneous resolution of HCG after evacuation of hydatidiform mole: comparison between complete and partial mole.
Matsui H; Iitsuka Y; Suzuka K; Seki K; Sekiya S
Hum Reprod; 2001 Jun; 16(6):1274-7. PubMed ID: 11387305
[TBL] [Abstract][Full Text] [Related]
32. Term delivery of a complete hydatidiform mole with a coexisting living fetus followed by successful treatment of maternal metastatic gestational trophoblastic disease.
Peng HH; Huang KG; Chueh HY; Adlan AS; Chang SD; Lee CL
Taiwan J Obstet Gynecol; 2014 Sep; 53(3):397-400. PubMed ID: 25286799
[TBL] [Abstract][Full Text] [Related]
33. [Expression and significance of LMP2 and PPM1A in gestational trophoblastic disease].
Zhang SS; Wan XY; Zhou CY; Lü WG; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2011 Jul; 46(7):510-5. PubMed ID: 22041443
[TBL] [Abstract][Full Text] [Related]
34. Predictors of persistent disease in women with complete hydatidiform mole.
Ayhan A; Tuncer ZS; Halilzade H; Küçükali T
J Reprod Med; 1996 Aug; 41(8):591-4. PubMed ID: 8866387
[TBL] [Abstract][Full Text] [Related]
35. Decidual immune cell infiltrate in hydatidiform mole.
Hussein MR; Abd-Elwahed AR; Abodeif ES; Abdulwahed SR
Cancer Invest; 2009 Jan; 27(1):60-6. PubMed ID: 19160109
[TBL] [Abstract][Full Text] [Related]
36. Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole.
Kim DS; Moon H; Kim KT; Moon YJ; Hwang YY
Obstet Gynecol; 1986 May; 67(5):690-4. PubMed ID: 3008055
[TBL] [Abstract][Full Text] [Related]
37. Hormonal contraception and trophoblastic sequelae after hydatidiform mole (a Gynecologic Oncology Group Study).
Curry SL; Schlaerth JB; Kohorn EI; Boyce JB; Gore H; Twiggs LB; Blessing JA
Am J Obstet Gynecol; 1989 Apr; 160(4):805-9; discussion 809-11. PubMed ID: 2540654
[TBL] [Abstract][Full Text] [Related]
38. [Risk factors for gestational trophoblastic tumors following complete hydatidiform mole].
Grzybowski W; Płoszyński A; Mielnik J; Adamcio-Deptulska M; Preis K; Wojciechowska D
Ginekol Pol; 2002 Nov; 73(11):1003-10. PubMed ID: 12722390
[TBL] [Abstract][Full Text] [Related]
39. Gestational trophoblastic disease following the evacuation of partial hydatidiform mole: a review of 66 cases.
Zalel Y; Dgani R
Eur J Obstet Gynecol Reprod Biol; 1997 Jan; 71(1):67-71. PubMed ID: 9031962
[TBL] [Abstract][Full Text] [Related]
40. Inhibin as a marker for hydatidiform mole: a comparative study with the determinations of intact human chorionic gonadotrophin and its free beta-subunit.
Badonnel Y; Barbé F; Legagneur H; Poncelet E; Schweitzer M
Clin Endocrinol (Oxf); 1994 Aug; 41(2):155-62. PubMed ID: 7523000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
